147 related articles for article (PubMed ID: 12968981)
1. Population pharmacokinetics of liposomal daunorubicin in children.
Hempel G; Reinhardt D; Creutzig U; Boos J
Br J Clin Pharmacol; 2003 Oct; 56(4):370-7. PubMed ID: 12968981
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia.
Bellott R; Auvrignon A; Leblanc T; Pérel Y; Gandemer V; Bertrand Y; Méchinaud F; Bellenger P; Vernois J; Leverger G; Baruchel A; Robert J
Cancer Chemother Pharmacol; 2001; 47(1):15-21. PubMed ID: 11221955
[TBL] [Abstract][Full Text] [Related]
3. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
[TBL] [Abstract][Full Text] [Related]
4. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia.
Pea F; Russo D; Michieli M; Baraldo M; Ermacora A; Damiani D; Baccarani M; Furlanut M
Cancer Chemother Pharmacol; 2000; 46(4):279-86. PubMed ID: 11052625
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
Fumagalli L; Zucchetti M; Parisi I; Viganò MG; Zecca B; Careddu A; D'Incalci M; Lazzarin A
Cancer Chemother Pharmacol; 2000; 45(6):495-501. PubMed ID: 10854138
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol.
Hempel G; Relling MV; de Rossi G; Stary J; De Lorenzo P; Valsecchi MG; Barisone E; Boos J; Pieters R
Pediatr Blood Cancer; 2010 Mar; 54(3):355-60. PubMed ID: 19731319
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
8. Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome.
Bellott R; Pouna P; Robert J
J Chromatogr B Biomed Sci Appl; 2001 Jun; 757(2):257-67. PubMed ID: 11417870
[TBL] [Abstract][Full Text] [Related]
9. Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia.
Piccaluga PP; Visani G; Martinelli G; Isidori A; Malagola M; Rondoni M; Baccarani M; Tura S
Leukemia; 2002 Sep; 16(9):1880-1. PubMed ID: 12200714
[No Abstract] [Full Text] [Related]
10. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin.
Zucchetti M; Boiardi A; Silvani A; Parisi I; Piccolrovazzi S; D'Incalci M
Cancer Chemother Pharmacol; 1999; 44(2):173-6. PubMed ID: 10412954
[TBL] [Abstract][Full Text] [Related]
11. [Immobilized forms of daunorubicin in patients with acute leukemia].
Isaev VG; Garmaeva TTs; Skorokhod AA; Parovichnikova EN; Tiurina NG; Kucher RA; Vitvitskiĭ VM; Ataullakhanov FI; Savchenko VG
Ter Arkh; 1999; 71(10):32-7. PubMed ID: 10612171
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
13. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study.
Fassas A; Buffels R; Anagnostopoulos A; Gacos E; Vadikolia C; Haloudis P; Kaloyannidis P
Br J Haematol; 2002 Feb; 116(2):308-15. PubMed ID: 11841431
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice.
Ying X; Wen H; Yao HJ; Zhang Y; Tian W; Zhang L; Ju RJ; Wang XX; Yu Y; Lu WL
Pharmacology; 2011; 87(1-2):105-14. PubMed ID: 21282968
[TBL] [Abstract][Full Text] [Related]
15. Phase II studies with DaunoXome in patients with nonresectable hepatocellular carcinoma: clinical and pharmacokinetic outcomes.
Yeo W; Chan KK; Mukwaya G; Ross M; Leung WT; Ho S; Chan AT; Johnson PJ
Cancer Chemother Pharmacol; 1999; 44(2):124-30. PubMed ID: 10412946
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of oral busulfan in children.
Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
[TBL] [Abstract][Full Text] [Related]
17. Liposomal daunorubicin (DaunoXome) in children with recurrent or progressive brain tumors.
Lippens RJ
Pediatr Hematol Oncol; 1999; 16(2):131-9. PubMed ID: 10100273
[TBL] [Abstract][Full Text] [Related]
18. Safety of high-dose liposomal daunorubicin (daunoxome) for refractory or relapsed acute myeloblastic leukaemia.
Fassas A; Buffels R; Kaloyannidis P; Anagnostopoulos A
Br J Haematol; 2003 Jul; 122(1):161-3. PubMed ID: 12823360
[No Abstract] [Full Text] [Related]
19. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia.
Bieker R; Lerchenmüller C; Wehmeyer J; Serve HL; Mesters RM; Büchner T; Berdel WE
Oncol Rep; 2003; 10(4):915-20. PubMed ID: 12792745
[TBL] [Abstract][Full Text] [Related]
20. Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia.
Pea F; Russo D; Michieli M; Damiani D; Fanin R; Michelutti A; Michelutti T; Piccolrovazzi S; Baccarani M; Furlanut M
Clin Pharmacokinet; 2003; 42(9):851-62. PubMed ID: 12882589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
